Elevation Oncology Licenses ADC Technology from Synaffix to Drive Pipeline Expansion

Licensing agreement gives Elevation Oncology access to Synaffix's ADC technology for one program in combination with SYNstatin E™Elevation Oncology nominates a novel HER3 ADC candidate EO-1022 leveraging its antibody as well as Synaffix's proprietary ADC development technologiesView original content:https://www.prnewswire.co.uk/news-releases/elevation-oncology-licenses-adc-technology-from-synaffix-to-drive-pipeline-expansion-302329298.html

en | boerse | 67940294 |